Cosmo Pharmaceuticals N.V (C43) — Financial Flexibility Index
Cosmo Pharmaceuticals N.V (C43) has a Financial Flexibility Index of 0.02x as of June 2022. Free cash flow of €7.39 Million (operating CF €6.28 Million minus capex €1.11 Million) represents 0% of total liabilities (€296.03 Million). Check how aggressively does Cosmo Pharmaceuticals N.V reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cosmo Pharmaceuticals N.V Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Cosmo Pharmaceuticals N.V across 10 annual periods. For the full cash flow conversion analysis, see Cosmo Pharmaceuticals N.V cash conversion from operations.
Annual Financial Flexibility Index for Cosmo Pharmaceuticals N.V (2016–2025)
Year-by-year free cash flow to debt coverage for Cosmo Pharmaceuticals N.V. Explore Cosmo Pharmaceuticals N.V cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.06x | €-7.02 Million | €-12.48 Million | €123.46 Million | ▼ -104.8% |
| 2024 | 1.19x | €168.06 Million | €162.41 Million | €141.68 Million | ▲ +196.8% |
| 2023 | 0.40x | €48.93 Million | €33.62 Million | €122.42 Million | ▲ +191.7% |
| 2022 | 0.14x | €40.54 Million | €33.23 Million | €295.80 Million | ▲ +121.8% |
| 2021 | 0.06x | €18.10 Million | €12.61 Million | €292.88 Million | ▼ -29.2% |
| 2020 | 0.09x | €17.11 Million | €12.98 Million | €196.04 Million | ▲ +200.6% |
| 2019 | -0.09x | €-16.60 Million | €-18.85 Million | €191.43 Million | ▼ -89.7% |
| 2018 | -0.05x | €-8.27 Million | €-10.16 Million | €180.83 Million | ▼ -144.5% |
| 2017 | 0.10x | €2.86 Million | €-9.43 Million | €27.86 Million | ▼ -92.9% |
| 2016 | 1.44x | €40.12 Million | €21.69 Million | €27.92 Million | — |